Home/Filings/4/0001209191-23-057239
4//SEC Filing

Rothera Mark 4

Accession 0001209191-23-057239

CIK 0001061027other

Filed

Dec 3, 7:00 PM ET

Accepted

Dec 4, 4:54 PM ET

Size

7.2 KB

Accession

0001209191-23-057239

Insider Transaction Report

Form 4
Period: 2023-11-30
Rothera Mark
DirectorPresident and CEO
Transactions
  • Purchase

    Common Stock

    2023-11-30$0.49/sh+52,094$25,73452,094 total
  • Purchase

    Common Stock

    2023-12-01$0.49/sh+47,906$23,627100,000 total
Footnotes (2)
  • [F1]Represents the weighted average share price of an aggregate total of 52,094 shares purchased in the price range of $0.48 to $0.51 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
  • [F2]Represents the weighted average share price of an aggregate total of 47,906 shares purchased in the price range of $0.4750 to $0.5130 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Issuer

Viracta Therapeutics, Inc.

CIK 0001061027

Entity typeother

Related Parties

1
  • filerCIK 0001550424

Filing Metadata

Form type
4
Filed
Dec 3, 7:00 PM ET
Accepted
Dec 4, 4:54 PM ET
Size
7.2 KB